As our results demonstrated the prognostic value of SLC1A5 and TALDO1 singularly in luminal breast cancer, we also established the co-expression impact of these markers on the clinical outcome and efficacy of adjuvant endocrine treatment. Here, TALDO1 is linked to breast cancer.